Requirement of the conserved, hydrophobic C-terminus region for the activation of heparanase

Experimental Cell Research

Volumn 314, Issue 15, 2008, Pages 2834-2845

  Lai, Ngit Shin ^a,b   Simizu, Siro ^a   Morisaki, Daiki ^a   Muroi, Makoto ^a   Osada, Hiroyuki ^a,b  

^a RIKEN   (Japan)

^b SAITAMA UNIVERSITY   (Japan)

Author keywords

Extracellular matrix; Glucuronidase; Glycosylation; Heparan sulfate; Heparanase; Invasion; Metastasis; Migration; Trafficking; Tumor cells

Indexed keywords

BETA GLUCURONIDASE; HEPARANASE;

AMINO ACID SUBSTITUTION; ARTICLE; CELL ACTIVATION; CELL INVASION; CELL MIGRATION; CELL SECRETION; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; GLYCOSYLATION; GOLGI COMPLEX; HUMAN; HUMAN CELL; HYDROPHOBICITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR CELL;

EID: 50049112962     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.07.004     Document Type: Article

References (46)

1. Bernfield M., Götte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., and Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68 (1999) 729-777
2. Esko J.D., and Selleck S.B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71 (2002) 435-471
3. Iozzo R.V., and San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 108 (2001) 349-355
4. Sasisekharan R., Shriver Z., Venkataraman G., and Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2 (2002) 521-528
5. Dempsey L.A., Brunn G.J., and Platt J.L. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem. Sci. 25 (2000) 349-351
6. Vlodavsky I., and Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108 (2001) 341-347
7. Bame K.J. Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 11 (2001) 91R-98R
8. Parish C.R., Freeman C., and Hulett M.D. Heparanase: a key enzyme involved in cell invasion. Biochim. Biophys. Acta 1471 (2001) M99-M108
9. Simizu S., Ishida K., and Osada H. Heparanase as a molecular target of cancer chemotherapy. Cancer Sci. 95 (2004) 553-558
10. Simizu S., Ishida K., Wierzba M.K., Sato T.A., and Osada H. Expression of heparanase in human tumor cell lines and human head and neck tumors. Cancer Lett. 193 (2003) 83-89
11. Koliopanos A., Friess H., Kleeff J., Shi X., Liao Q., Pecker I., Vlodavsky I., Zimmermann A., and Büchler M.W. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 61 (2001) 4655-4659
12. El-Assal O.N., Yamanoi A., Ono T., Kohno H., and Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin. Cancer Res. 7 (2001) 1299-1305
13. Mikami S., Ohashi K., Usui Y., Nemoto T., Katsube K., Yanagishita M., Nakajima M., Nakamura K., and Koike M. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn. J. Cancer Res. 92 (2001) 1062-1073
14. Shteper P.J., Zcharia E., Ashhab Y., Peretz T., Vlodavsky I., and Ben-Yehuda D. Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 22 (2003) 7737-7749
15. Toyoshima M., and Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. J. Biol. Chem. 274 (1999) 24153-24160
16. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I., Spector L., and Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5 (1999) 793-802
17. Hulett M.D., Freeman C., Hamdorf B.J., Baker R., Harris M.J., and Parish C.R. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5 (1999) 803-809
18. Fairbanks M.B., Mildner A.M., Leone J.W., Cavey G.S., Mathews W.R., Drong R.F., Slightom J.L., Bienkowski M.J., Smith C.W., Bannow C.A., and Heinrikson R.L. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J. Biol. Chem. 274 (1999) 29587-29590
19. Kussie P.H., Hulmes J.D., Ludwig D.L., Patel S., Navarro E.C., Seddon A.P., Giorgio N.A., and Bohlen P. Cloning and functional expression of a human heparanase gene. Biochem. Biophys. Res. Commun. 261 (1999) 183-187
20. Nadav L., Eldor A., Yacoby-Zeevi O., Zamir E., Pecker I., Ilan N., Geiger B., Vlodavsky I., and Katz B.Z. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J. Cell Sci. 115 (2002) 2179-2187
21. Gingis-Velitski S., Zetser A., Kaplan V., Ben-Zaken O., Cohen E., Levy-Adam F., Bashenko Y., Flugelman M.Y., Vlodavsky I., and Ilan N. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J. Biol. Chem. 279 (2004) 44084-44092
22. Vreys V., Delande N., Zhang Z., Coomans C., Roebroek A., Dürr J., and David G. Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J. Biol. Chem. 280 (2005) 33141-33148
23. Ilan N., Elkin M., and Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 38 (2006) 2018-2039
24. Cohen E., Atzmon R., Vlodavsky I., and Ilan N. Heparanase processing by lysosomal/endosomal protein preparation. FEBS Lett. 579 (2005) 2334-2338
25. Simizu S., Ishida K., Wierzba M.K., and Osada H. Secretion of heparanase protein is regulated bu glycosylation in human tumor cell lines. J. Biol. Chem. 279 (2004) 2697-2703
26. Simizu S., Suzuki T., Muroi M., Lai N.S., Takagi S., Dohmae N., and Osada H. Involvement of disulfide bond formation in the activation of heparanase. Cancer Res. 67 (2007) 7841-7849
27. Simizu S., Takagi S., Tamura Y., and Osada H. RECK-mediated suppression of tumor cell invasion is regulated by glycosylation in human tumor cell lines. Cancer Res. 65 (2005) 7455-7461
28. Simizu S., Tamura Y., and Osada H. Dephosphorylation of Bcl-2 by protein phosphatase 2A results in apoptosis resistance. Cancer Sci. 95 (2004) 266-270
29. Simizu S., and Osada H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat. Cell Biol. 2 (2000) 852-854
30. Ishida K., Wierzba M.K., Teruya T., Simizu S., and Osada H. Novel heparan sulfate mimetic compounds as antitumor agents. Chem. Biol. 11 (2004) 367-377
31. Ishida K., Hirai G., Murakami K., Teruya T., Simizu S., Sodeoka M., and Osada H. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. Mol. Cancer Ther. 3 (2004) 1069-1077
32. Nakajima M., Irimura T., Di Ferrante D., Di Ferrante N., and Nicolson G.L. Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 220 (1983) 611-613
33. Bertolesi G.E., Michaiel G., and McFarlane S. Two heparanase splicing variants with distinct properties are necessary in early Xenopus development. J. Biol. Chem. 283 (2008) 16004-16016
34. Santa T., Takeda A., Uchiyama S., Fukushima T., Homma H., Suzuki S., Yokosu H., Lim C.K., and Imai K. N-(4-nitro-2,1,3-benzoxadiazoyl-7-yl)-N-methyl-2-aminoacetohydrazide (NBD-CO-Hz) as a precolumn fluorescent derivatization reagent for carboxylic acids in high-performance liquid chromatography. J. Pharm. Biomed. Anal 17 (1998) 1065-1070
35. Tamura Y., Simizu S., and Osada H. The phosphorylation status and anti-apoptotic activity of Bcl-2 are regulated by ERK and protein phosphatase 2A on the mitochondria. FEBS Lett. 569 (2004) 249-255
36. Liu C., Yao J., de Belle I., Huang R.P., Adamson E., and Mercola D. The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-b1, fibronectin, and plasminogen activator inhibitor-1. J. Biol. Chem. 274 (1999) 4400-4411
37. Brown J.A., and Swank R.T. Subcellular redistribution of newly synthesized macrophage lysosomal enzymes. Correlation between delivery to the lysosomes and maturation. J. Biol. Chem. 258 (1983) 15323-15328
38. Albini A., Iwamoto Y., Kleinman H.K., Martin G.R., Aaronson S.A., Kozlowski J.M., and McEwan R.N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47 (1987) 3239-3245
39. Teruya T., Simizu S., Kanoh N., and Osada H. Phoslactomycin targets cysteine-269 of the protein phosphatase 2A catalytic subunit in cells. FEBS Lett. 579 (2005) 2463-2468
40. Kyte J., and Doolittle R. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157 (1982) 105-132
41. Brodsky J.L. The protective and destructive roles played by molecular chaperones during ERAD (endoplasmic-reticulum-associated degradation). Biochem. J. 404 (2007) 353-363
42. Goldshmidt O., Zcharia E., Aingorn H., Guatta-Rangini Z., Atzmon R., Michal I., Pecker I., Mitrani E., and Vlodavsky I. Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence. J. Biol. Chem. 276 (2001) 29178-29187
43. Goldshmidt O., Zcharia E., Abramovitch R., Metzger S., Aingorn H., Friedmann Y., Schirrmacher V., Mitrani E., and Vlodavsky I. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10031-10036
44. Cao W., and Matherly L.H. Analysis of the membrane topology for transmembrane domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility methods. Biochem. J. 378 (2004) 201-206
45. Joyce J.A., Freeman C., Meyer-Morse N., Parish C.R., and Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24 (2005) 4037-4051
46. Basche M., Gustafson D.L., Holden S.N., O'Bryant C.L., Gore L., Witta S., Schultz M.K., Morrow M., Levin A., Creese B.R., Kangas M., Roberts K., Nguyen T., Davis K., Addison R.S., Moore J.C., and Eckhardt S.G. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin. Cancer Res. 12 (2006) 5471-5480